ELISA News and Research

RSS

Compelling evidence of SARS-CoV-2 exposure and neutralizing antibodies in domestic cats in Peru

Although Peru is one of the countries most affected by the pandemic, no studies had been conducted to investigate SARS-CoV-2 seroprevalence among domestic cats. Recently, researchers from Peru demonstrated the presence of neutralizing antibodies for the receptor binding-domain (RBD) of the SARS-CoV-2 spike protein in cats in Lima, Peru. The owners of the cats in the study had confirmed SARS-CoV-2 infection.

1 Jun 2021

A novel multiplexed diagnostic approach for COVID-19

Researchers developed a platform for detecting the virus directly from a patient's sample as well as the immune response through antibodies such as IgG and IgM.

31 May 2021

Previous H3N2 influenza A infection may explain some cases of severe COVID-19

According to research from the University of California, some cases of severe coronavirus disease 2019 (COVID-19) may be related to the immunological memory of previous H3N2 influenza A infection.

26 May 2021

Study attempts to standardize humoral immune Correlates of Protection (CoP) in COVID-19

A new study aims to identify antibody-based biomarkers associated with the humoral immune response that could be a standard CoP candidate for COVID-19. Further, standardization of research methods to measure these biomarkers has also been conducted.

25 May 2021

Biorbyt receives Queen’s Award for Enterprise

Biorbyt is delighted to have been honoured with a Queen’s Award for Enterprise for its outstanding achievements in international trade.

From Biorbyt 24 May 2021

Human monoclonal antibodies neutralize SARS-CoV-2 in an Fc-independent manner

Researchers from Israel recently isolated a set of SARS-CoV-2 neutralizing monoclonal antibodies from blood samples of patients with severe COVID-19. They were the first to show that transgenic K18-hACE2 mice infected with lethal doses of SARS-CoV-2 can be fully protected by administering antibodies even 3 days after infection

19 May 2021

A possible human-to-canine transmission of SARS-CoV-2

Now, researchers at the U.S. Centers for Disease Control and Prevention (CDC) identified a case of human to animal transmission when SARS-CoV-2 was detected in a healthy poodle dog living with four family members who had COVID-19.

18 May 2021

Nanotechnology and COVID-19 diagnosis and treatment

The development of nano-biosensors and nanoparticle-based vaccines and medicines has opened a new path toward better management of the coronavirus disease 2019 (COVID-19) pandemic. In a recently published article in the journal ACS Biomaterials Science & Engineering, scientists have reviewed recent advancements in nanotechnology-based diagnostic and therapeutic interventions against human coronaviruses.

17 May 2021

A SARS-CoV-2 neutralizing antibody with extensive spike binding coverage

In a recently published research paper in the journal Nature Communications, a team of scientists from China has described the antiviral efficacy of a novel anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody isolated from recovered coronavirus disease 2019 (COVID-19) patients.

17 May 2021

Antibodies generated by malaria cross-react with SARS-CoV-2

An international team of researchers has warned that individuals with acute malaria infection generate high levels of antibodies that cross-react with the viral spike protein of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19).

13 May 2021

Immunity developed by SARS-CoV-2 infection can protect against E484K variants, suggests study

A team of scientists from Japan has recently investigated the neutralizing potency of convalescent sera against currently circulating SARS-CoV-2 variants with multiple spike mutations.

13 May 2021

Pfizer-BioNTech COVID-19 vaccine effective in patients with myeloproliferative neoplasms

Researchers in the UK have provided evidence that Pfizer-BioNTech’s coronavirus disease 2019 (COVID-19) vaccine induces effective immune responses in patients with myeloproliferative neoplasms.

13 May 2021

An intranasal COVID-19 vaccine elicits long-lasting immunity against SARS-CoV-2 variants in vivo

A team of scientists from the Washington University School of Medicine and the University of Texas Medical Branch, USA, has recently evaluated the durability and robustness of an adenovirus-vectored, spike-based intranasal COVID-19 vaccine in mice.

11 May 2021

3D printing technique extends the possibilities of lateral flow tests

Researchers at KU Leuven (Belgium) have developed a 3D printing technique that extends the possibilities of lateral flow testing.

10 May 2021

Researchers study how cancer cells re-organize 3D structure of DNA to ramp up oncogene activity

In cancer, a lot of biology goes awry: Genes mutate, molecular processes change dramatically, and cells proliferate uncontrollably to form entirely new tissues that we call tumors.

10 May 2021

New nanoimmunoassay can detect anti–SARS-CoV-2 antibodies in ultralow-volume blood samples

In a recent study, researchers developed and validated a nanoimmunoassay (NIA) that analyzes 1,024 samples in parallel on a single microfluidic device the size of a USB stick. They detected anti-SARS-CoV-2 IgG antibodies, achieving a sensitivity of 98% and specificity of 100% based on an analysis of 134 pre-pandemic sera (collected in 2013/2014 and 2018) and 155 sera from reverse transcription-polymerase chain reaction (RT-PCR) positive individuals.

10 May 2021

Prevalence of SARS-CoV-2 antibodies in Germany

Seroprevalence studies have proved their worth in estimating the size and directionality of an outbreak of infectious disease, especially the current pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced coronavirus disease 2019 (COVID-19). A new study posted to the medRxiv* preprint server describes the prevalence of SARS-CoV-2 antibodies in five representative regions of Germany.

10 May 2021

Large-scale study focuses on COVID-19 antibodies in asymptomatic and symptomatic patients

MUSC Hollings Cancer Center researchers added to the understanding of the protective immune response against the SARS-CoV-2 virus in a study published in April in iScience.

6 May 2021

Guidance on diagnosis and management of cerebral venous sinus thrombosis after a COVID-19 vaccine

Last Friday, the Centers for Disease Control and Prevention and the U.S. Food & Drug Administration lifted the pause in administration of the Johnson & Johnson (Janssen) COVID-19 vaccine in the U.S.

29 Apr 2021

Study examines smoking behavior after the implementation of California law

Smoking is the leading cause of preventable death in America and causes about 30% of all cancer deaths. That's why researchers with the UC Davis Comprehensive Cancer Center wanted to study the impact of a California law passed in 2016 that raised the tobacco sales age from 18 to 21.

26 Apr 2021

ELISA News and Research

Compelling evidence of SARS-CoV-2 exposure and neutralizing antibodies in domestic cats in Peru

A novel multiplexed diagnostic approach for COVID-19

Previous H3N2 influenza A infection may explain some cases of severe COVID-19

Study attempts to standardize humoral immune Correlates of Protection (CoP) in COVID-19

Biorbyt receives Queen’s Award for Enterprise

Human monoclonal antibodies neutralize SARS-CoV-2 in an Fc-independent manner

A possible human-to-canine transmission of SARS-CoV-2

Nanotechnology and COVID-19 diagnosis and treatment

A SARS-CoV-2 neutralizing antibody with extensive spike binding coverage

Antibodies generated by malaria cross-react with SARS-CoV-2

Immunity developed by SARS-CoV-2 infection can protect against E484K variants, suggests study

Pfizer-BioNTech COVID-19 vaccine effective in patients with myeloproliferative neoplasms

An intranasal COVID-19 vaccine elicits long-lasting immunity against SARS-CoV-2 variants in vivo

3D printing technique extends the possibilities of lateral flow tests

Researchers study how cancer cells re-organize 3D structure of DNA to ramp up oncogene activity

New nanoimmunoassay can detect anti–SARS-CoV-2 antibodies in ultralow-volume blood samples

Prevalence of SARS-CoV-2 antibodies in Germany

Large-scale study focuses on COVID-19 antibodies in asymptomatic and symptomatic patients

Guidance on diagnosis and management of cerebral venous sinus thrombosis after a COVID-19 vaccine

Study examines smoking behavior after the implementation of California law

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News